MedPath

The PEERLESS Study

Not Applicable
Completed
Conditions
Pulmonary Thrombo-embolism
Pulmonary Embolism
Registration Number
NCT05111613
Lead Sponsor
Inari Medical
Brief Summary

A prospective, multicenter, randomized controlled trial of the FlowTriever System compared to Catheter-Directed Thrombolysis (CDT) for use in the treatment of acute pulmonary embolism. The trial includes a non-randomized cohort of subjects with an absolute contraindication to thrombolysis.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
692
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Composite clinical endpoint constructed as a win ratio, a hierarchy of the following:Hospital discharge or at 7 days after the index procedure, whichever is sooner

1. All-cause mortality, or

2. Intracranial hemorrhage (ICH), or

3. Major bleeding per ISTH definition, or

4. Clinical deterioration defined by hemodynamic or respiratory worsening, and/or escalation to a bailout therapy, or

5. ICU admission and ICU length-of-stay during the index hospitalization and following the index procedure.

Secondary Outcome Measures
NameTimeMethod
Device and drug-related serious adverse events30 days from index procedure
Intracranial hemorrhage (ICH)Hospital discharge or at 7 days after the index procedure, whichever is sooner
All-cause mortalityHospital discharge or at 7 days after the index procedure, whichever is sooner
Clinical deterioration defined by hemodynamic or respiratory worsening, and/or escalation to a bailout therapyHospital discharge or at 7 days after the index procedure, whichever is sooner
Pulmonary Embolism Quality of Life (PEmb-QOL)At 30 day visit
Composite clinical endpoint constructed as a win ratio hierarchy of the following four components:Hospital discharge or at 7 days after the index procedure, whichever is sooner

* All-cause mortality, or

* Intracranial hemorrhage (ICH), or

* Major bleeding per ISTH definition, or

* Clinical deterioration defined by hemodynamic or respiratory worsening, and/or escalation to a bailout therapy

Major bleeding per ISTH definitionHospital discharge or at 7 days after the index procedure, whichever is sooner
Clinically Relevant Non-Major (CRNM) and Minor bleeding eventsHospital discharge or at 7 days after the index procedure, whichever is sooner
Change in right-ventricular/left-ventricular (RV/LV) ratio, as measured by echocardiography or CTBaseline to 24 hour visit
EQ-5D-5L Quality of LifeAt 30 day visit
ICU admission and ICU length of stay during the index hospitalization and following the index procedureHospital discharge or at 7 days after the index procedure, whichever is sooner
All cause mortality30 days from index procedure
Modified Medical Research Council (mMRC) dyspnea scoreAt 24 hour and 30 day visits

The range of scores is zero to four (worse)

Length of total hospital stay and post-index-procedure hospital stayTo a maximum of 30 days
PE-related and all-cause readmission30 days from index procedure

Trial Locations

Locations (60)

Brigham and Women's Hospital

🇺🇸

Boston, Massachusetts, United States

Loma Linda University Health

🇺🇸

Loma Linda, California, United States

Providence St. Joseph Orange

🇺🇸

Orange, California, United States

Huntington Hospital

🇺🇸

Pasadena, California, United States

University of Colorado Hospital

🇺🇸

Aurora, Colorado, United States

Radiology and Imaging Associates

🇺🇸

Lakeland, Florida, United States

Baptist Health South Florida

🇺🇸

Miami, Florida, United States

Sarasota Memorial Hospital

🇺🇸

Sarasota, Florida, United States

Tallahassee Memorial Hospital

🇺🇸

Tallahassee, Florida, United States

University of South Florida Tampa General Hospital

🇺🇸

Tampa, Florida, United States

Scroll for more (50 remaining)
Brigham and Women's Hospital
🇺🇸Boston, Massachusetts, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.